Nurtec ODT vs Emgality
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Nurtec ODT | US Emgality | |
|---|---|---|
| Generic name | rimegepant | galcanezumab |
| Drug class | CGRP Receptor Antagonist | CGRP Antagonist (Biologic) |
| Treats | Migraine (acute and preventive) | Migraine prevention, cluster headache |
| Category | Neurology | Neurology |
| Manufacturer | Pfizer | Eli Lilly |
| Year approved | 2020 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $190M | $110M |
| Common side effects | Nausea, Stomach pain, Indigestion, Allergic reactions | Injection site reactions, Constipation, Itching, Allergic reactions |
Nurtec ODT
Frequently asked questions
Is Nurtec ODT or Emgality better?
Neither is universally "better." Nurtec ODT (rimegepant) and Emgality (galcanezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nurtec ODT and Emgality?
Nurtec ODT is a CGRP Receptor Antagonist made by Pfizer, while Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nurtec ODT has the larger estimated TV advertising budget of the two.